MIRA
MIRA Pharmaceuticals, Inc.
0.95
2 x 0.67
2 x 1.22
bid
ask
+
0.00
0.08%
2 @ 08:41 AM
0.93 -0.02 (2.25%)
| Ytd | -37.26% | |
| 1y | -21.71% |
0.92
day range
0.96
0.90
52 week range
2.45
| Open | 0.96 | Prev Close | 0.95 | Low | 0.92 | High | 0.96 | Mkt Cap | 39.81M |
| Vol | 31.85K | Avg Vol | 123.44K | EPS | -1.27 | P/E | N/A | Forward P/E | -2.14 |
| Beta | N/A | Short Ratio | 0.47 | Inst. Own | 5.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.00 | 200-d Avg | 1.25 | 1yr Est | 12.08 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.18 | -0.14 | 0.04 | 22.22% |
| 2024-08-13 | 2024-06 | -0.1 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -0.1 | -0.11 | -0.01 | -10.00% |
| 2024-05-13 | 2024-03 | -0.1 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.1 | -0.12 | -0.02 | -20.00% |
| 2023-11-13 | 2023-09 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-09-30 | Rodman & Renshaw | Upgrade | Buy | |
| 2024-08-05 | Ascendiant Capital | Upgrade | Buy |
Profile
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-19 | AMINOV EREZ | Chief Executive Officer | 1.06M | Sale |
| 2023-08-06 | CAPPY GEORGE | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-08-27 | MCNULTY BRIAN PATRICK | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Cross Staff Investments Inc. | 365.90K | 384.20K | 2.21% |
| 2024-09-29 | Geode Capital Management, LLC | 115.91K | 121.71K | 0.70% |
| 2024-09-29 | Suncoast Equity Management | 90.00K | 94.50K | 0.54% |
| 2024-09-29 | LPL Financial LLC | 50.00K | 52.50K | 0.30% |
| 2024-09-29 | Schonfeld Strategic Advisors Llc | 41.90K | 43.99K | 0.25% |
| 2024-09-29 | Millennium Management Llc | 40.73K | 42.76K | 0.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 60.37K | 63.39K | 0.36% |
| 2024-10-30 | Fidelity Total Market Index Fund | 21.89K | 22.99K | 0.13% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 16.18K | 16.99K | 0.10% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 9.46K | 9.93K | 0.06% |